Advaxis (ADXS) : During the past 4 weeks, traders have been relatively bearish on Advaxis (ADXS), hence the stock is down -6.7% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.18% relative to the S&P 500. The 4-week change in the price of the stock is -7.2% and the stock has fallen -1.02% in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.87% and the 50-Day Moving Average is 7.39%.The 200 Day SMA reached 17.7%
Advaxis (NASDAQ:ADXS): After opening at $10.5, the stock dipped to an intraday low of $10.14 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $10.77 and the buying power remained strong till the end. The stock closed at $10.69 for the day, a gain of 2.89% for the day session. The total traded volume was 631,765. The stocks close on the previous trading day was $10.69.
Advaxis (ADXS) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $26 and the lowest price target forecast is $20. The average forecast of all the analysts is $23.6 and the expected standard deviation is $2.3.
Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.